

Special Issue

Genetics, Genomics, and Precision Medicine in Colorectal Cancer

Message from the Guest Editors

Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide, resulting both from germline pathogenic genetic variants and sequential acquisition and accumulation of somatic genomic alterations. Pharmacogenetics and pharmacogenomics affect the choice of therapeutic strategies, directing the selection of specific drugs and their dosing for CRC patients. The role of genetic and genomic determinants as diagnostic, prognostic, and therapeutic biomarkers, as well as targets of drug treatment, is robustly increasing year after year. Approval in past years of anti-EGFR monoclonal antibodies, immune checkpoint inhibitors, and protein kinase inhibitors of oncogenic mutations, such as BRAFV600E, has improved the overall survival of CRC patients that, however, remains limited, especially in the metastatic setting. Thus, more advanced knowledge is needed to improve current clinical results. The aim of this Special Issue is to collect original research articles and reviews on genetics and genomics that might offer relevant insights in the prediction of CRC diagnosis, prognosis, and therapeutic outcome, leading to improvement of precision medicine in CRC.

Guest Editors

Prof. Dr. Enrico Mini

Department of Health Sciences, Universita degli Studi di Firenze, Florence, Italy

Dr. Stefania Nobili

Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/108827

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



Deadline for manuscript submissions

closed (15 August 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](http://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).